<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T02:35:54Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2072/461803" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2072/461803</identifier><datestamp>2025-06-12T09:13:47Z</datestamp><setSpec>com_2072_98</setSpec><setSpec>col_2072_378192</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Humoral Responses and Ex Vivo IFN-γ Production after Canine Whole Blood Stimulation with Leishmania infantum Antigen or KMP11 Recombinant Protein</dc:title>
   <dc:creator>Martínez-Orellana, Pamela</dc:creator>
   <dc:creator>González, Noemí</dc:creator>
   <dc:creator>Baldassarre, Antonella</dc:creator>
   <dc:creator>Álvarez-Fernández, Alejandra</dc:creator>
   <dc:creator>Ordeix, Laura (Ordeix i Esteve)</dc:creator>
   <dc:creator>Paradies, Paola</dc:creator>
   <dc:creator>Soto, Manuel</dc:creator>
   <dc:creator>Solano Gallego, Laia</dc:creator>
   <dc:subject>Leishmaniosis</dc:subject>
   <dc:subject>Serology</dc:subject>
   <dc:subject>Dog</dc:subject>
   <dc:subject>Cell-mediated immunity</dc:subject>
   <dc:subject>Diagnosis</dc:subject>
   <dc:description>The effect of Leishmania infantum soluble antigen (LSA) and recombinant Kinetoplastid Membrane Protein 11 (rKMP11) on the induction of ex vivo specific IFN-γ (n = 69) and antibody responses (n = 108) was determined in dogs. All dogs were tested for serological response to both antigens and divided into Group 1: healthy (Asturias, Spain, n = 26), Group 2: sick (n = 46), Group 3: healthy Ibizan hounds (Mallorca, Spain, n = 22) and Group 4: healthy (Bari, Italy, n = 14). Antibody levels were higher for LSA when compared to rKMP11 (p = 0.001). Ibizan hounds were all seronegative to rKMP11 and 18% were low seropositive to LSA. Sick dogs presented higher antibody response to both antigens compared to the rest of the groups (p &lt; 0.0001). All groups showed higher IFN-γ levels after LSA compared to rKMP11 responses (p &lt; 0.05). The highest response to LSA was found in Ibizan hounds (p &lt; 0.05). IFN-γ to LSA and rKMP11 stimulation was observed in 34% and in 2.8% of the sick dogs, respectively. Here, we demonstrated that anti-rKMP11 antibodies are mainly present in dogs with moderate to severe disease. Furthermore, cellular immune response measured by specific ex vivo IFN-γ production was more intense to LSA than stimulated to rKMP11.</dc:description>
   <dc:date>2022</dc:date>
   <dc:type>Article</dc:type>
   <dc:identifier>https://ddd.uab.cat/record/257221</dc:identifier>
   <dc:identifier>urn:10.3390/vetsci9030116</dc:identifier>
   <dc:identifier>urn:oai:ddd.uab.cat:257221</dc:identifier>
   <dc:identifier>urn:articleid:23067381v9n3p116</dc:identifier>
   <dc:identifier>urn:pmid:35324844</dc:identifier>
   <dc:identifier>urn:pmc-uid:8954708</dc:identifier>
   <dc:identifier>urn:pmcid:PMC8954708</dc:identifier>
   <dc:identifier>urn:oai:pubmedcentral.nih.gov:8954708</dc:identifier>
   <dc:identifier>urn:oai:egreta.uab.cat:publications/fe4374f8-8333-416d-bc84-b15d9756a36d</dc:identifier>
   <dc:identifier>urn:scopus_id:85126706486</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>Ministerio de Economía y Competitividad AGL2015-68477</dc:relation>
   <dc:relation>Veterinary sciences ; Vol. 9 Núm. 3 (2022), p. 116</dc:relation>
   <dc:rights>open access</dc:rights>
   <dc:rights>Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.</dc:rights>
   <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher/>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>